{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:57:41Z","timestamp":1790873861267,"version":"4.1.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharmacotherapies often provide delayed or incomplete relief and may increase the risk of treatment-emergent affective switching. Recent evidence highlights the therapeutic potential of NMDA receptor antagonists, particularly ketamine and its S-enantiomer esketamine, as rapid-acting antidepressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review synthesizes findings from randomized controlled trials, systematic reviews, and real-world studies investigating ketamine and esketamine in treatment-resistant bipolar depression. Emphasis was placed on antidepressant efficacy, safety, and the risk of mood destabilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across multiple trials, ketamine produced rapid and robust antidepressant effects, with significant improvement in depressive symptoms within hours of administration. Data confirmed high response rates in treatment-resistant bipolar depression, while rapid-onset benefits with minimal switch risk. Further there is evidence on comparable efficacy and safety of intranasal esketamine in bipolar and unipolar depression, with no cases of mania or hypomania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ketamine and esketamine represent mechanistically novel and clinically effective treatments for bipolar depression. Their rapid antidepressant action and low switch liability distinguish them from traditional antidepressants. Esketamine, with its favorable tolerability and intranasal administration, offers a promising adjunctive option for treatment-resistant bipolar depression. Long-term data are warranted to optimize maintenance strategies and confirm sustained safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1777402","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:19:06Z","timestamp":1772615946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"R.","family":"Queissner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fellendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Z.","family":"Reininghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","first-page":"27","article-title":"The neurobiology of bipolar disorder: a comprehensive review of the literature","volume":"11","author":"Fountoulakis","year":"2012","journal-title":"Ann Gen Psychiatry"},{"key":"B2","first-page":"874561","article-title":"Neural circuit mechanisms in mania: an integrative model","volume":"13","author":"Cotovio","year":"2022","journal-title":"Front Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.01022.x","article-title":"The functional neuroanatomy of bipolar disorder: a consensus model","volume":"14","author":"Strakowski","year":"2012","journal-title":"Bipolar Disord"},{"key":"B4","first-page":"105372","article-title":"Structural and functional brain network alterations in bipolar disorder: recent advances and clinical implications","volume":"163","author":"Herrera","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B5","article-title":"Plasma amino acids related to central nervous system function in patients with bipolar disorder","volume":"145","author":"Hoekstra","year":"2006","journal-title":"Psychiatry Res"},{"key":"B6","article-title":"Glutamatergic mechanisms in the pathophysiology and treatment of mood disorders","volume":"70","author":"Ferensztajn-Rochowiak","year":"2018","journal-title":"Pharmacol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.07.109","article-title":"The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis","volume":"276","author":"Fornaro","year":"2020","journal-title":"J Affect Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a multicentric real-world study","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of depressive symptoms in patients at imminent risk for suicide: a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B13","article-title":"Ketamine combined with electroconvulsive therapy for treatment-resistant depression: a systematic review and meta-analysis","volume":"246","author":"Wang","year":"2019","journal-title":"J Affect Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/ph16020182","article-title":"Pharmacological treatment of bipolar depression: A review of observational studies","volume":"16","author":"Fellendorf","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2025.04.006","article-title":"Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder","volume":"128","author":"Rengasamy","year":"2025","journal-title":"Brain Behavior Immun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-02931-3","article-title":"The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors","volume":"30","author":"Rizzo","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B19","article-title":"Antidepressant potential of (S)-ketamine in comparison with (R)-ketamine in animal models of depression","volume":"81","author":"Fukumoto","year":"2017","journal-title":"Biol Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1777402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:19:07Z","timestamp":1772615947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1777402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":19,"alternative-id":["10.3389\/fpsyt.2026.1777402"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1777402","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1777402"}}